Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.

被引：0
|
作者：
Wang, Ying
Choueiri, Toni K.
Lee, Jae-Lyun
Tan, Min-Han
Rha, Sun Young
North, Scott A.
Kollmannsberger, Christian K.
Heng, Daniel Yick Chin
机构：
[1] Univ Calgary, Calgary, AB, Canada
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Natl Canc Ctr, Singapore, Singapore
[5] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[6] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[7] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[8] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期
关键词：
D O I：
10.1200/jco.2012.30.5_suppl.451
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
451
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
    Wang, Y.
    Choueiri, T. K.
    Lee, J-L
    Tan, M-H
    Rha, S. Y.
    North, S. A.
    Kollmannsberger, C. K.
    McDermott, D. F.
    Heng, D. Y. C.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 110 (06) : 1433 - 1437
  • [2] Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
    Y Wang
    T K Choueiri
    J-L Lee
    M-H Tan
    S Y Rha
    S A North
    C K Kollmannsberger
    D F McDermott
    D Y C Heng
    [J]. British Journal of Cancer, 2014, 110 : 1433 - 1437
  • [3] Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
    Ng, C. F.
    Kwon, T. G.
    Eto, M.
    Miyake, H.
    Seo, S. I.
    Byun, S-S.
    Lee, J. L.
    Rosbrook, B.
    Grande, E.
    Gross-Goupil, M.
    Quinn, D. I.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [4] Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC)
    Negrier, S.
    Chabaud, S.
    Escudier, B.
    Ravaud, A.
    Chevreau, C.
    Blay, J. Y.
    Delva, R.
    Biota, C.
    Perol, D.
    Menetrier-Caux, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] CLINICAL OUTCOME OF ASIAN VS. NON-ASIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WITH CONTINUOUS ONCE-DAILY DOSING OF SUNITINIB AS FIRST-LINE THERAPY
    Barrios, C. H.
    Hernandez-Barajas, D.
    Brown, M. P.
    Lee, S.
    Fein, L.
    Liu, J.
    Hariharan, S.
    Martell, B.
    Yuan, J.
    Rha, S. Y.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 286 - 286
  • [6] Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium.
    Choueiri, Toni K.
    Xie, Wanling
    Harshman, Lauren Christine
    Bjarnason, Georg A.
    Knox, Jennifer J.
    MacKenzie, Mary J.
    Wood, Lori
    Vaishampayan, Ulka N.
    Tan, Min-Han
    Rha, Sun Young
    Donskov, Frede
    Agarwal, Neeraj
    Kollmannsberger, Christian K.
    North, Scott A.
    Rini, Brian I.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [7] An exploratory study of radium-223 and vascular endothelial growth factor targeted therapy (VEGF TT) in patients (pts) with metastatic renal cell carcinoma (mRCC) and bone metastases (BM).
    McKay, Rana R.
    Gray, Kathryn P.
    Polacek, Laura
    Pomerantz, Mark M.
    Krajewski, Katherine M.
    Jacene, Heather
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] Vascular Endothelial Growth Factor-targeted Therapy in Metastatic Renal Cell Carcinoma
    Rini, Brian I.
    [J]. CANCER, 2009, 115 (10) : 2306 - 2312
  • [9] Differences in Characteristics and Outcomes Between Asian and Non-Asian Patients in the TIAregistry.org
    Hoshino, Takao
    Uchiyama, Shinichiro
    Wong, Lawrence K. S.
    Sissani, Leila
    Albers, Gregory W.
    Bornstein, Natan M.
    Caplan, Louis R.
    Donnan, Geoffrey A.
    Ferro, Jose M.
    Hennerici, Michael G.
    Labreuche, Julien
    Lavallee, Philippa C.
    Molina, Carlos
    Rothwell, Peter M.
    Steg, Philippe Gabriel
    Touboul, Pierre-Jean
    Vicaut, Eric
    Amarenco, Pierre
    [J]. STROKE, 2017, 48 (07) : 1779 - +
  • [10] RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis
    Yang, L.
    Alyasova, A.
    Ye, D.
    Karpenko, A.
    Li, H.
    Alekseev, B.
    Xie, L.
    Kurteva, G.
    Kowalyszyn, R.
    Karyakin, O.
    Neron, Y.
    Cosgriff, T.
    Collins, L.
    Brechenmacher, T.
    Lin, J.
    Morgan, L.
    Motzer, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S524 - S524
12345